Literature DB >> 2846652

Evaluation of immunoglobulin G preparations for anti-cytomegalovirus antibodies with reference to neutralizing antibody in the presence of complement.

Y Eizuru1, I Ueno, Y Minamishima.   

Abstract

Eighteen commercially available immunoglobulin G (IgG) preparations were evaluated by various methods for anti-cytomegalovirus (CMV) antibodies. The modifications of immunoglobulin G molecules, such as sulfonation, alkylation, and enzyme treatments, resulted in profound reductions in anti-CMV antibody titers. However, after reversion in vitro, sulfonated IgG preparations which have been shown to be reverted in vivo (Y. Masuho, K. Tomibe, K. Matsuzawa, T. Watanabe, S. Ishimoto, S. Tsunoda, and T. Noguchi, J. Biochem. 79:1377-1379, 1976) restored the anti-CMV antibody titers to levels comparable with those of nonsulfonated IgG preparations. There is no good correlation among the titers tested by different methods. As a method which reflects the biological activities in vivo, the neutralization test in the presence of complement is suitable for the evaluation of IgG preparations.

Mesh:

Substances:

Year:  1988        PMID: 2846652      PMCID: PMC266739          DOI: 10.1128/jcm.26.9.1881-1883.1988

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  15 in total

1.  Protective effect of early serum from mice after cytomegalovirus infection.

Authors:  T P Araullo-Cruz; M Ho; J A Armstrong
Journal:  Infect Immun       Date:  1978-09       Impact factor: 3.441

2.  Appearance of IgG (Fc) receptor(s) on cultured human fibroblasts infected with human cytomegalovirus.

Authors:  A A Rahman; M Teschner; K K Sethi; H Brandis
Journal:  J Immunol       Date:  1976-07       Impact factor: 5.422

3.  Assessment of the presence of cytomegalovirus-neutralizing antibody by a plaque-reduction assay.

Authors:  R B Lewis; D S Matzke; T B Albrecht; R B Pollard
Journal:  Rev Infect Dis       Date:  1986 Jul-Aug

4.  Treatment of cytomegalovirus pneumonitis with hyperimmune plasma.

Authors:  B A Dijkmans; J Versteeg; R H Kauffmann; P J van den Broek; J G Eernisse; J J van Zanten; W Bakker; M W Kalff; J P van Hooff
Journal:  Lancet       Date:  1979-04-14       Impact factor: 79.321

5.  Microneutalization of cytomegalovirus.

Authors:  H Stalder; A Ehrensberger
Journal:  J Infect Dis       Date:  1980-07       Impact factor: 5.226

6.  An IgG-Fc receptor induced in cytomegalovirus-infected human fibroblasts.

Authors:  R Keller; R Peitchel; J N Goldman; M Goldman
Journal:  J Immunol       Date:  1976-03       Impact factor: 5.422

7.  Treatment of life-threatening infections in renal transplant recipients with high-dose intravenous human IgG.

Authors:  R M Condie; B L Hall; R J Howard; D Fryd; R L Simmons; J S Najarian
Journal:  Transplant Proc       Date:  1979-03       Impact factor: 1.066

8.  Reconstruction of intact gamma-globulin from S-sulfonated gamma-globulin in vivo.

Authors:  Y Masuho; K Tomibe; K Matsuzawa; T Watanabe; S Ishimoto
Journal:  J Biochem       Date:  1976-06       Impact factor: 3.387

9.  Development of an intravenous gamma-globulin with Fc activities. II. Reconversion of S-sulfonated human gamma-globulin into the original gamma-globulin.

Authors:  Y Masuho; K Tomibe; T Watanabe; Y Fukumoto
Journal:  Vox Sang       Date:  1977       Impact factor: 2.144

10.  Comparison of the neutralizing and ELISA antibody titres to human cytomegalovirus (HCMV) in human sera and in gamma globulin preparations.

Authors:  H Schmitz; S Essuman
Journal:  J Med Virol       Date:  1986-10       Impact factor: 2.327

View more
  1 in total

1.  Novel microneutralization assay for HCMV using automated data collection and analysis.

Authors:  Anna Maria Abai; Larry R Smith; Mary K Wloch
Journal:  J Immunol Methods       Date:  2007-02-23       Impact factor: 2.303

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.